Market & Macro
U.S. stocks fell sharply on October 22, with the S&P 500 down 1.21% and the Nasdaq-100 down 2.9%. Is this a replay of 2022? We compare the two periods and explain why waiting and building cash may be the most sensible approach for now.
Investment Strategy
We sold Walgreens (WBA) at a 18% loss in late 2023. When Sycamore Partners took the company private at $11.45 per share in 2025, it was clear that cutting our losses was the right call. Here is our original thesis, the red flags we saw, and why we sold.
Investment Strategy
S&P 500 and gold ETFs are often seen as reliable long-term growth assets, but history shows they can stall for more than a decade. We tested dollar-cost averaging through past sideways markets to see how investors would have fared, and what it means for buying near a peak today.
Investment Strategy
With U.S. stocks drifting sideways and AI optimism under pressure, should you wait or keep investing? We tested a $100-a-month strategy starting at the 2021 tech peak across five assets. The results point to a simple, low-stress approach.
Stock Insight
Cyberattacks have surged throughout October 2026, fueled by agentic AI, and could drive higher security budgets across governments and corporations. We screened the sector on technical factors and found four cybersecurity stocks worth watching, along with a caution on Varonis after its buyout news.
Stock Insight
The Nasdaq-100 fell 2.5% as credit stress at CoreWeave, sticky inflation and slowing growth at OpenAI and Anthropic rattled AI stocks. Some names now look cheap, but is it a real buying opportunity or a trap? Here’s what’s driving the drop and what investors should watch next.
Index & ETF Watch
With inflation at 3.7% and traders pricing in a possible December rate hike, the Fed’s next move is unclear. Here is how to compare the most popular S&P 500, Nasdaq-100 and global ETFs, and build a simple long-term plan by buying in steps.
Mikirduit US helps everyday investors understand what drives a stock, how the business is performing, and whether the current valuation makes sense.
We sold Walgreens (WBA) at a 18% loss in late 2023. When Sycamore Partners took the company private at $11.45 per share in 2025, it was clear that cutting our losses was the right call. Here is our original thesis, the red flags we saw, and why we sold.
With U.S. stocks drifting sideways and AI optimism under pressure, should you wait or keep investing? We tested a $100-a-month strategy starting at the 2021 tech peak across five assets. The results point to a simple, low-stress approach.
Cyberattacks have surged throughout October 2026, fueled by agentic AI, and could drive higher security budgets across governments and corporations. We screened the sector on technical factors and found four cybersecurity stocks worth watching, along with a caution on Varonis after its buyout news.
The Nasdaq-100 fell 2.5% as credit stress at CoreWeave, sticky inflation and slowing growth at OpenAI and Anthropic rattled AI stocks. Some names now look cheap, but is it a real buying opportunity or a trap? Here’s what’s driving the drop and what investors should watch next.
Quarterly earnings explained through revenue, margins, cash flow, guidance, and the numbers that matter.
Fair value, historical multiples, peer comparisons, and scenario-based valuation for U.S. stocks.
Corporate actions, acquisitions, buybacks, regulation, and company developments moving stocks.
Fed policy, inflation, jobs, yields, commodities, and market trends shaping stocks.
Independent Stock Research, Earnings Analysis, and Valuation for Everyday Investors
Accenture (ACN) is trading below its own five-year valuation averages, but it isn’t cheap compared with its peers. Here are three things to understand about its acquisitions, backlog, and AI exposure before you add it to your watchlist.
SpaceX’s $8 billion spectrum purchase has revived U.S. cell tower stocks that many investors had written off. We compare American Tower, Crown Castle, and SBA Communications on tower footprint, debt, growth, and valuation to see which looks best.
Five REITs offer yields of roughly 6%–9% after sharp sell-offs. We compare VICI, GLPI, Realty Income, WPC, and NHI on AFFO valuation, tenant health, and funding risks.
How does a small investing community balance dividend stocks, AI-driven momentum picks, and plenty of cash? Mikirduit shares its five-strategy framework, its staged buying rules, and the real results behind its U.S. stock picks, including a loss it took along the way.
Pfizer (NYSE: PFE) offers a dividend yield of about 5-6 percent, but patent expirations, rising competition, and falling EPS cloud the outlook. Here is what investors should weigh.
Logitech's quarterly profit surged 61%, helped by a one-time tariff refund. But the peripheral maker is warning that a chip shortage could cost it up to $200 million in sales during the all-important holiday quarter.
SpaceX, Rocket Lab and AST SpaceMobile are racing to connect phones, ships and data centers from orbit. Our fair-value models show all three trading above base-case estimates, with catalysts that stretch from late 2026 to 2028.
Betterware de Mexico (NYSE: BWMX) has closed its Tupperware acquisition and now offers an estimated dividend yield of about 8%. We break down H1 2026 results, management guidance, 2026-2027 forecasts, fair value and the risks investors should weigh before buying.
Nineteen stocks pay dividends in October 2026, and three offer the biggest yields: BDN, GIS and Verizon. Only one looks like a healthy income play, while the other two have yields inflated by steep price declines.
Funds that double, triple or flip the returns of the S&P 500 and Nasdaq-100 have posted big numbers this year. Here is how leveraged and inverse ETFs work, what they have delivered through Oct. 2, 2026, and why they are built for short-term traders, not buy-and-hold investors.
Coca-Cola shares are up 23% this year while PepsiCo has slid 12.5%. As GLP-1 weight-loss drugs change how Americans shop, PepsiCo's heavy snack and North American exposure leaves it cheaper, but riskier.
Micron topped Wall Street forecasts with $54.23 billion in quarterly revenue, but its stock barely moved. Analysts say the boom is driven more by price hikes than by volume, raising questions about how long the growth can last.
Mikirduit US is a global financial research publication focused primarily on U.S. stocks and financial markets. We analyze businesses, earnings, valuation, corporate actions, and market developments using primary sources and fundamental research.
Learn more about Mikirduit US →